Electrocardiographic effects of HBI-3000 (sulcardine sulfate), a new drug for termination of atrial fibrillation
Sulcardine increased the QTc and PR intervals, QRS and P-wave durations, and HR dose dependently. The T-wave segment JTpc was significantly decreased, whereas the T peak to T end interval was significantly increased. These findings predict an anti-atrial fibrillation effect via inhibition of 1 or more cardiac ion channels. The strong block of the rapid component of the delayed rectifier potassium channel current was partially mitigated by JTp shortening, probably owing to late sodium current and L-type calcium current inhibition, reducing the risk of proarrhythmia by decreasing repolarization time.
Authors
- Stephanie H. Stanworth
- Jerome B. Riebman
- Suzanne J. Romano
- Jay W. Mason (ORCID: https://orcid.org/0000-0002-5713-9906)
- Boaz Mendzelevski (ORCID: https://orcid.org/0000-0003-2122-7215)
- Gary Elliott
- Fabio Badilini
- Martino Vaglio
- Mireille Gillings
Institutions
- University of Utah (US)
- Galena Biopharma (United States) (US)
- ISCO International (United States) (US)
- Cambridge Consultants (United Kingdom) (GB)
- Stantec (Canada) (CA)
Publication Details
- Journal
- Heart Rhythm O2
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1016/j.hroo.2025.11.019
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00